Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
m |
|||
| Line 21: | Line 21: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| + | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:ALK inhibitors]] | [[Category:ALK inhibitors]] | ||
Revision as of 01:12, 14 May 2022
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)
Patient Drug Information
Also known as
- Code name: ASP2215
- Brand name: Xospata